New hope for advanced prostate cancer: experimental drug enters human trials
NCT ID NCT05800665
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 34 times
Summary
This early-stage trial is testing an experimental oral drug called RO7656594 in people with advanced or metastatic prostate cancer that has progressed after standard treatments. The study aims to find safe doses and check for any signs that the drug can shrink tumors or lower PSA levels. About 210 participants will receive the drug at different doses to see how well it is tolerated and how the body processes it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center - PPDS
RECRUITINGSeoul, 05505, South Korea
-
Austin Hospital
RECRUITINGHeidelberg, Victoria, 3084, Australia
-
British Columbia Cancer Agency
RECRUITINGVancouver, British Columbia, V5Z 4E6, Canada
-
Cambridge Clinical Research Centre
RECRUITINGCambridge, CB2 0AU, United Kingdom
-
Centre Léon Bérard
RECRUITINGLyon, 69008, France
-
Clinica Universidad de Navarra
RECRUITINGPamplona, Navarre, 31008, Spain
-
Clinica Universidad de Navarra-Madrid
RECRUITINGMadrid, 28027, Spain
-
HonorHealth
RECRUITINGScottsdale, Arizona, 85258, United States
-
Hospital Clinico San Carlos
RECRUITINGMadrid, 28040, Spain
-
Hospital Universitario Vall d'Hebron - PPDS
RECRUITINGBarcelona, 08035, Spain
-
Institut Gustave Roussy
RECRUITINGVillejuif, 94805, France
-
Institut Paoli Calmettes
RECRUITINGMarseille, 13009, France
-
Leicester Royal Infirmary
RECRUITINGLeicester, LE1 5WW, United Kingdom
-
Macquarie University Hospital
RECRUITINGNew South Wales, New South Wales, 2162, Australia
-
Monash Health Monash Medical Centre
RECRUITINGClayton, Victoria, 3168, Australia
-
Princess Margaret Hospital
RECRUITINGToronto, Ontario, M5G 2M9, Canada
-
Royal Marsden Hospital - Surrey
RECRUITINGSutton, SM2 5PT, United Kingdom
-
SCRI Oncology Partners
RECRUITINGNashville, Texas, 37203, United States
-
Samsung Medical Center - PPDS
RECRUITINGSeoul, 06351, South Korea
-
Sarah Cannon Research Institute @ Florida Cancer
RECRUITINGOrlando, Florida, 32827, United States
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
Severance Hospital Yonsei University Health System - PPDS
RECRUITINGSeoul, 03722, South Korea
-
St Vincent's Hospital Sydney
RECRUITINGDarlinghurst, New South Wales, 2010, Australia
-
The Christie
RECRUITINGManchester, M20 4BX, United Kingdom
-
University of Illinois Hospital & Health Sciences System
RECRUITINGChicago, Illinois, 60612, United States
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06510, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RO7656594 (also called GDC-2992), an oral drug
What this could lead to
If successful, this could point toward a new treatment option for advanced prostate cancer that has stopped responding to other therapies.
What could go wrong
This is an early Phase 1 trial with only 210 participants, focused on safety and dosing. It is too soon to know if the drug will work or have manageable side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.